Cargando…

Combining Radiotherapy With Anti-angiogenic Therapy and Immunotherapy; A Therapeutic Triad for Cancer?

Radiotherapy has been used for the treatment of cancer for over a century. Throughout this period, the therapeutic benefit of radiotherapy has continuously progressed due to technical developments and increased insight in the biological mechanisms underlying the cellular responses to irradiation. In...

Descripción completa

Detalles Bibliográficos
Autores principales: Goedegebuure, Ruben S. A., de Klerk, Leonie K., Bass, Adam J., Derks, Sarah, Thijssen, Victor L. J. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6339950/
https://www.ncbi.nlm.nih.gov/pubmed/30692993
http://dx.doi.org/10.3389/fimmu.2018.03107
_version_ 1783388717868646400
author Goedegebuure, Ruben S. A.
de Klerk, Leonie K.
Bass, Adam J.
Derks, Sarah
Thijssen, Victor L. J. L.
author_facet Goedegebuure, Ruben S. A.
de Klerk, Leonie K.
Bass, Adam J.
Derks, Sarah
Thijssen, Victor L. J. L.
author_sort Goedegebuure, Ruben S. A.
collection PubMed
description Radiotherapy has been used for the treatment of cancer for over a century. Throughout this period, the therapeutic benefit of radiotherapy has continuously progressed due to technical developments and increased insight in the biological mechanisms underlying the cellular responses to irradiation. In order to further improve radiotherapy efficacy, there is a mounting interest in combining radiotherapy with other forms of therapy such as anti-angiogenic therapy or immunotherapy. These strategies provide different opportunities and challenges, especially with regard to dose scheduling and timing. Addressing these issues requires insight in the interaction between the different treatment modalities. In the current review, we describe the basic principles of the effects of radiotherapy on tumor vascularization and tumor immunity and vice versa. We discuss the main strategies to combine these treatment modalities and the hurdles that have to be overcome in order to maximize therapeutic effectivity. Finally, we evaluate the outstanding questions and present future prospects of a therapeutic triad for cancer.
format Online
Article
Text
id pubmed-6339950
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-63399502019-01-28 Combining Radiotherapy With Anti-angiogenic Therapy and Immunotherapy; A Therapeutic Triad for Cancer? Goedegebuure, Ruben S. A. de Klerk, Leonie K. Bass, Adam J. Derks, Sarah Thijssen, Victor L. J. L. Front Immunol Immunology Radiotherapy has been used for the treatment of cancer for over a century. Throughout this period, the therapeutic benefit of radiotherapy has continuously progressed due to technical developments and increased insight in the biological mechanisms underlying the cellular responses to irradiation. In order to further improve radiotherapy efficacy, there is a mounting interest in combining radiotherapy with other forms of therapy such as anti-angiogenic therapy or immunotherapy. These strategies provide different opportunities and challenges, especially with regard to dose scheduling and timing. Addressing these issues requires insight in the interaction between the different treatment modalities. In the current review, we describe the basic principles of the effects of radiotherapy on tumor vascularization and tumor immunity and vice versa. We discuss the main strategies to combine these treatment modalities and the hurdles that have to be overcome in order to maximize therapeutic effectivity. Finally, we evaluate the outstanding questions and present future prospects of a therapeutic triad for cancer. Frontiers Media S.A. 2019-01-14 /pmc/articles/PMC6339950/ /pubmed/30692993 http://dx.doi.org/10.3389/fimmu.2018.03107 Text en Copyright © 2019 Goedegebuure, de Klerk, Bass, Derks and Thijssen. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Goedegebuure, Ruben S. A.
de Klerk, Leonie K.
Bass, Adam J.
Derks, Sarah
Thijssen, Victor L. J. L.
Combining Radiotherapy With Anti-angiogenic Therapy and Immunotherapy; A Therapeutic Triad for Cancer?
title Combining Radiotherapy With Anti-angiogenic Therapy and Immunotherapy; A Therapeutic Triad for Cancer?
title_full Combining Radiotherapy With Anti-angiogenic Therapy and Immunotherapy; A Therapeutic Triad for Cancer?
title_fullStr Combining Radiotherapy With Anti-angiogenic Therapy and Immunotherapy; A Therapeutic Triad for Cancer?
title_full_unstemmed Combining Radiotherapy With Anti-angiogenic Therapy and Immunotherapy; A Therapeutic Triad for Cancer?
title_short Combining Radiotherapy With Anti-angiogenic Therapy and Immunotherapy; A Therapeutic Triad for Cancer?
title_sort combining radiotherapy with anti-angiogenic therapy and immunotherapy; a therapeutic triad for cancer?
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6339950/
https://www.ncbi.nlm.nih.gov/pubmed/30692993
http://dx.doi.org/10.3389/fimmu.2018.03107
work_keys_str_mv AT goedegebuurerubensa combiningradiotherapywithantiangiogenictherapyandimmunotherapyatherapeutictriadforcancer
AT deklerkleoniek combiningradiotherapywithantiangiogenictherapyandimmunotherapyatherapeutictriadforcancer
AT bassadamj combiningradiotherapywithantiangiogenictherapyandimmunotherapyatherapeutictriadforcancer
AT derkssarah combiningradiotherapywithantiangiogenictherapyandimmunotherapyatherapeutictriadforcancer
AT thijssenvictorljl combiningradiotherapywithantiangiogenictherapyandimmunotherapyatherapeutictriadforcancer